Cargando…
Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease
BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) were shown to delay chronic kidney disease (CKD) progression in patients with hypertension and/or heart failure (HF) and proteinuria. OBJECTIVE: We conducted a systematic literature review on real-world evidence to identify the literature gap...
Autores principales: | Folkerts, Kerstin, Millier, Aurelie, Smela, Beata, Olewinska, Elzbieta, Schmedt, Niklas, Mernagh, Paul, Kovesdy, Csaba P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227157/ https://www.ncbi.nlm.nih.gov/pubmed/36422853 http://dx.doi.org/10.1007/s40620-022-01492-w |
Ejemplares similares
-
High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database
por: Fried, Linda, et al.
Publicado: (2022) -
Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors
por: Kovesdy, Csaba, et al.
Publicado: (2022) -
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020) -
Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2021) -
Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)